MajorAtypical antipsychotic – dibenzodiazepine×Antituberculous antibiotic
Updated · Methodology
Mechanism
In the liver, CYP1A2 and CYP3A4 metabolise almost all of the clozapine, with some contribution from CYP2C19 and CYP2D6 (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Rifampicin is a strong inducer of drug-metabolising enzymes, including the cytochrome P450 enzymes CYP1A2 and CYP3A4 (rifampicin SmPC, AEMPS, section 4.5). The US Food and Drug Administration (FDA) classes it as a strong CYP3A4 inducer (US Clozaril label, FDA, section 7.1). As a result, clozapine blood levels can fall when the two drugs are taken together, and the treatment can become less effective (Spanish clozapine SmPC, AEMPS, section 4.5; US Clozaril label, FDA, section 7.1). When rifampicin is stopped, clozapine levels can rise, and so can the risk of adverse reactions (US Clozaril label, FDA, section 7.1). Both drugs can harm the liver. Severe and sometimes fatal hepatotoxicity has been reported with clozapine (US Clozaril label, FDA, section 5.12). Rifampicin is prescribed with other hepatotoxic drugs only when necessary (rifampicin SmPC, AEMPS, section 4.4).
Symptoms
Clozapine can become less effective, and psychotic symptoms can worsen (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). After rifampicin is stopped, clozapine levels can rise, and so can the risk of adverse reactions. These include seizures, whose risk depends on the clozapine dose (US Clozaril label, US Food and Drug Administration, FDA, sections 5.4 and 7.1). Liver injury during clozapine treatment presents with fatigue, malaise, loss of appetite, nausea and jaundice (US Clozaril label, FDA, section 5.12). Cholestasis from rifampicin causes itching, weakness, loss of appetite, nausea, vomiting, abdominal pain, yellowing of the eyes or skin and dark urine (rifampicin SmPC, AEMPS, section 4.4).
Management
The US Food and Drug Administration (FDA) does not recommend taking clozapine with strong CYP3A4 inducers and names rifampicin among them (US Clozaril label, FDA, sections 2.7 and 7.1). If the combination cannot be avoided, the clozapine dose may need to be increased and its effectiveness monitored (US Clozaril label, FDA, section 2.7). The Spanish clozapine SmPC asks prescribers to take into account that cytochrome P450 inducers, including rifampicin, can reduce the effectiveness of clozapine. It lists these combinations under precautions that include dose adjustment (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Doses of drugs affected by rifampicin may need adjusting both when it is started and when it is stopped (rifampicin SmPC, AEMPS, section 4.5). After rifampicin is stopped, consider lowering the clozapine dose, because clozapine levels and the risk of adverse reactions can rise (US Clozaril label, FDA, section 7.1). Rifampicin is prescribed with other drugs that can damage the liver only when necessary, with caution and under strict medical supervision. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are measured before treatment and then every 2–4 weeks (rifampicin SmPC, AEMPS, section 4.4). During clozapine treatment, watch for signs of liver injury and run liver tests (US Clozaril label, FDA, section 5.12). If liver test values rise to more than three times the upper limit of normal or jaundice appears, clozapine treatment is interrupted, and it can be restarted only if liver function tests are normal (Spanish clozapine SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Rifaldin 300 mg cápsulas (rifampicina) (2026)– AEMPS, CIMA, nº registro 46029, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Clozapina – Leponex (nº registro 59547), sección 4.5 (2026)– AEMPS, CIMA, nº registro 59547, revisión 06/2026, secciones 4.4 y 4.5
- FDA: Clozaril (clozapine) prescribing information (2025)– FDA, DailyMed, HLS Therapeutics, setid 90876802-0e3a-44c9-9ff7-1754dfbe736a, v21, 06/2025, sections 5.1, 5.4, 5.5, 7.1
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), sección 4.4 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos), revisión 06/2026, secciones 4.3 y 4.4
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), secciones 4.9 y 5.2 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos, Viatris), revisión 06/2026, secciones 4.9 y 5.2
- AEMPS: Ficha técnica: Rifampicina, Rifaldin 300 mg (nº registro 46029), sección 4.4 (2026)– AEMPS, CIMA, nº registro 46029 (Rifaldin 300 mg cápsulas, Sanofi Aventis), revisión 04/2026 (texto revisado 03/2026), secciones 4.4 y 4.8